The Drug Enforcement Administration’s (DEA) proposal to classify concentrated forms of 7-hydroxymitragynine (7-OH), a potent alkaloid derived from the kratom plant, as a Schedule I controlled substance has unleashed a torrent of public comments, primarily from individuals who rely on the substance for chronic pain management. As of July 24, more than 20,000 comments had been submitted to the Department of Health and Human Services (HHS), painting a stark picture of desperation and fear among users who credit 7-OH with significantly improving their quality of life. The overwhelming response echoes a similar public outcry in 2016 that led the DEA to reverse its plans to ban kratom itself, suggesting a potential record for public engagement on a federal regulatory issue.
The Human Cost: Voices from the Front Lines of Chronic Pain
At the heart of this regulatory battle are thousands of personal narratives, many of which highlight the profound impact 7-OH has had on individuals grappling with debilitating chronic pain. Leigh Ann Matthews, a 51-year-old woman living alone on less than $2,000 per month without health insurance, embodies the vulnerability of many affected. She depends on 7-OH for pain relief and faces an uncertain future should it become illegal. "Please don’t make me suffer with chronic pain by taking away the ONLY thing that has helped me tremendously," Matthews implored in her submission to the Federal Register. "I have no family or friends to lean on or help me. I don’t abuse 7-OH. I’m so afraid." Her words reflect a pervasive anxiety among users who feel their only effective and accessible pain management option is on the verge of being stripped away.
The sentiment of regaining a lost life resonates deeply within the comments. A search for the phrase "my life back" within the submitted comments yields 290 results, while "chronic pain" appears in 2,608 submissions. These figures underscore the widespread reliance on 7-OH among a population often underserved by traditional medical pathways, particularly concerning pain management.
Gabriel Duley, a 50-year-old man living with multiple sclerosis, shared his struggle: "I live my life with chronic pain. It is so hard to get out of bed to even take a shower. Doctors do not prescribe pain medications. Please do not take 7-OH away. It’s the only thing that has given my life back to me." His testimony illustrates the growing challenge many face in accessing conventional pain relief amidst the ongoing opioid crisis, leaving them to seek alternative solutions.
Another poignant account comes from Tyler Bartone, a 30-year-old Ohio resident who has endured chronic pain since a motorcycle accident at age 22 left both his legs broken. Bartone recounted his journey through conventional pharmaceuticals: "Oxycodone, hydrocodone, Suboxone, and tramadol all got tried over those years, and none of them let me function the way I needed to." He found relief with 7-OH, enabling him to "walk my dogs now. I can play with my kids. I stopped relying on opioid pain medication because this actually worked for my pain in a way [that] those didn’t." Bartone’s experience highlights a common theme: 7-OH is often a last resort after other treatments, including prescription opioids, have failed or proven unsuitable. He reported maintaining a steady dosage of 30 to 60 mg of 7-OH spread across 4 to 5 doses a day for one to two years, indicating a stable and non-escalating pattern of use.
The Looming Threat: Public Health Implications of a Ban
The potential ban carries significant public health implications, as articulated by users like Bartone. He warned of a dangerous dilemma: "People in my situation, and others I know who rely on 7-OH daily just to function, would be left with two options: go back to opioid prescriptions that didn’t work as well, or turn to street drugs. I know people would die from that second option. That is the real hazard here, not the milligrams in a tested tablet." This fear is not unfounded, as a sudden cutoff of an effective pain management tool can push vulnerable individuals towards illicit and often more dangerous alternatives, potentially exacerbating the existing overdose crisis.
Katherine Loperena, a 33-year-old sales professional who manages chronic pain with more than 60 mg of 7-OH daily, echoed these concerns, stating, "What scares me most is going back to the days when chronic pain decided whether I could work or not. I lost jobs because the pain became too much to push through, and I spent years choosing between showing up in agony or protecting my income." Her testimony underscores the profound economic and social consequences for individuals whose ability to function and contribute to society is directly tied to their access to effective pain relief. Like Bartone, Loperena had previously tried various treatments, including oxycodone, alcohol, cannabis, and over-the-counter pain relievers, without finding adequate relief.
Lindsay Huffman, who has managed chronic pain for five years with 7-OH, affirmed its critical role: "Without it, I would have no way to treat my pain. It has been massively beneficial to my quality of life. Banning it would affect thousands of people who just want to be able to function and have finally found some hope."
Simpler, yet equally impactful, comments like Kyle Whitman’s "Please don’t do this" and Lane Reeves’ "This should be available for chronic pain patients with no insurance!!" encapsulate the desperation and practical needs driving the public response.
Rolando Smith, who uses 25-50 mg of 7-OH daily, described how it has made his life "so much more enjoyable through the ability to no longer feel immense pain all day long." He emphasized a key distinction from other pain medications: "I take 7-OH not to feel anything such as a high, but rather to just eliminate the feeling of pain that usually lasts hours each day. 7-OH is a perfect substance for my pain compared to other painkillers I have received as I am not a fan of overly euphoric or ‘high’ feeling drugs." Smith also reported no issues with withdrawal or dependence, citing a year of on-and-off use and ease in quitting to lower tolerance.
Patricia Metz, who relies on 7-OH a few times a week for chronic pain from a serious injury, shared her fear of being unable to work and provide for her child if access is removed. "This product has given me back a quality of life I couldn’t otherwise have," Metz wrote. "I have had six surgeries, countless hours of physical therapy, and spent years working with pain management with no meaningful result. 7-hydroxymitragynine is far safer than prescription pain management and far more accessible." Her concerns about driving individuals to "dangerous and deadly street drugs" if 7-OH is banned echo those of Bartone and others.
The Regulatory Landscape: 7-OH, Kratom, and Schedule I Classification
The proposed scheduling by the DEA targets concentrated forms of 7-OH, an alkaloid found in Mitragyna speciosa, commonly known as kratom. Kratom is a tropical evergreen tree in the coffee family, native to Southeast Asia, where its leaves have been traditionally used for their stimulant and opioid-like effects. While kratom contains over 40 alkaloids, mitragynine is the most abundant, and 7-OH is present in much smaller quantities but is significantly more potent. The DEA’s move suggests a concern over the increasing availability and use of concentrated forms of 7-OH, particularly in products marketed for pain relief or recreational use, which may pose higher risks due to their potency and lack of regulation.
A Schedule I classification, according to the Controlled Substances Act, signifies that a substance has:
- A high potential for abuse.
- No currently accepted medical use in treatment in the United States.
- A lack of accepted safety for use under medical supervision.
This classification is typically reserved for drugs like heroin, LSD, and ecstasy. Opponents of the 7-OH ban argue that this classification is inappropriate, given the anecdotal evidence of therapeutic benefits and the reported lack of severe abuse potential or withdrawal symptoms comparable to Schedule I opioids by many users. They also point to ongoing scientific research into kratom and its alkaloids, suggesting that further study, not outright prohibition, is warranted.
The DEA’s proposed scheduling order limits the amount of 7-OH to no more than 0.05% of a product by weight or volume, which translates to approximately 0.5 mg of 7-OH per tablet. This threshold is considered "unrealistic" by many users and advocates. Tyler Bartone, for instance, reported taking 30 to 60 mg daily, a dosage dramatically higher than the proposed limit. "I’m asking HHS to set any threshold based on how people actually take this, not a number that erases the product entirely," Bartone urged. This suggests that the proposed limit would effectively ban virtually all existing 7-OH products currently on the market, rendering them illegal.
The Review Process and Historical Precedent
The Department of Health and Human Services (HHS) plays a crucial role in this process. Before the DEA can finalize a scheduling decision, HHS must provide a scientific and medical evaluation and a scheduling recommendation. The public comments currently flooding the Federal Register are directed to HHS, intended to inform their review and recommendation. This public input is critical, as it provides real-world data and perspectives on the substance’s use, effects, and the potential impact of a ban.
This isn’t the first time the DEA has faced significant public backlash over kratom. In 2016, the agency announced plans to temporarily place kratom’s main active components – mitragynine and 7-hydroxymitragynine – into Schedule I. This proposal triggered an unprecedented public outcry, with over 22,000 comments submitted to the Federal Register, a record at the time. Advocacy groups, scientists, and chronic pain patients united to protest the ban, arguing it would eliminate a safe and effective alternative to opioids and drive users to illicit markets. Faced with this overwhelming opposition and calls for further scientific review, the DEA ultimately withdrew its intent to ban kratom, instead issuing a public notice to solicit more comments and scientific data. This historical precedent offers a glimmer of hope for current 7-OH users, demonstrating that sustained public engagement can influence federal regulatory decisions.
Industry Perspectives and Calls for Regulation
Adding a layer of complexity to the debate is the stance of the American Kratom Association (AKA), which represents natural leaf kratom vendors. While generally advocating for the legality and responsible regulation of kratom, the AKA is in favor of banning concentrated 7-OH products. The organization recently sent a letter to HHS, claiming that many of the public comments in support of 7-OH are "Coordinated, Duplicate, Fictitious, and Financially Incentivized." According to the AKA, these personal stories should not be given the same weight as scientific analysis in determining an appropriate 7-OH threshold. They also alleged that some 7-OH vendors are offering discounts to consumers who demonstrate they have left a comment, suggesting an orchestrated campaign.
The AKA’s position stems from a desire to protect the broader kratom market, which they believe is threatened by highly potent, concentrated products that could be more prone to abuse or adverse effects. They argue that such products might undermine the public perception of natural kratom, potentially leading to broader bans. Instead, the AKA advocates for regulations that ensure product purity, accurate labeling, and age restrictions for natural kratom products.
Users like Tyler Bartone, while opposing the ban, also expressed support for sensible regulation. He stated he would back rules that "keep this market honest," including a 21-and-up age requirement, mandatory lab testing with published results, child-resistant packaging, and clear dosage labeling. Such proposals suggest a middle ground where public safety concerns can be addressed without resorting to outright prohibition, allowing access for those who genuinely benefit from 7-OH for medicinal purposes.
Broader Implications and the Path Forward
The potential ban on 7-OH highlights several broader issues in drug policy and public health. It underscores the challenges of regulating natural substances that fall outside traditional pharmaceutical development pathways, even if they demonstrate therapeutic potential. It also reflects the ongoing struggle to balance public safety concerns, particularly in the context of the opioid crisis, with the needs of chronic pain patients who often find themselves caught between inadequate conventional treatments and unregulated alternatives.
The deadline for public comments on the scheduling of 7-OH is July 31. The sheer volume of submissions already received signals a potent and organized public response, likely surpassing the record set during the 2016 kratom debate. What follows will be a critical period of review by HHS, followed by the DEA’s final decision. The outcome will not only determine the future availability of 7-OH but also set a precedent for how the federal government approaches the regulation of emerging natural compounds that offer relief to thousands, yet lack the rigorous clinical trials associated with approved pharmaceuticals. For Leigh Ann Matthews, Tyler Bartone, and countless others, the stakes could not be higher.
